Skip to main content

Table 3 Number of positive immunostaining results in different subgroups and corresponding p-values.

From: Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas

 

Triple-negative

ER+/PR+/HER2-

p-value

Basal-like

Non-basal-like

p-value

Cytoplasmic PRDX III

3 (8.1%)

9 (21.4%)

0.10

2 (6.5%)

1 (16.7%)

0.42

Nuclear PRDX III

3 (8.1%)

10 (23.8%)

0.060

3 (9.7%)

0 (0.0%)

0.43

Cytoplasmic PRDX IV

27 (73.0%)

20 (47.6%)

0.022

22 (71.0%)

5 (83.3%)

0.53

8-OHdG

13 (37.1%)

30 (73.2%)

0.0016

10 (33.3%)

3 (60.0%)

0.25

Nrf2

12 (33.3%)

11 (26.8%)

0.53

10 (33.3%)

2 (33.3%)

1.0

Keap1

26 (76.5%)

16 (39.0%)

0.0011

22 (78.6%)

4 (66.7%)

0.53

  1. Criteria for positive immunostaining for each antibody are described in the Materials and Methods section.